
IKT
Inhibikase Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.800
Open
1.790
VWAP
--
Vol
57.54K
Mkt Cap
131.58M
Low
1.740
Amount
--
EV/EBITDA(TTM)
--
Total Shares
7.22M
EV
38.40M
EV/OCF(TTM)
--
P/S(TTM)
--
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Show More
1 Analyst Rating

346.93% Upside
Wall Street analysts forecast IKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKT is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

346.93% Upside
Current: 1.790

Low
8.00
Averages
8.00
High
8.00

346.93% Upside
Current: 1.790

Low
8.00
Averages
8.00
High
8.00
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-28
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Strong Buy
to
Hold
Downgrades
n/a
2025-02-12
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-02-12
Downgrades
Strong Buy
to
Hold
Reason
Jefferies
Dennis Ding
Strong Buy
Initiates
$8
2024-11-08
Reason
Jefferies
Dennis Ding
Price Target
$8
2024-11-08
Initiates
Strong Buy
Reason
Jefferies initiated coverage of Inhibikase Therapeutics with a Buy rating and $8 price target. The stock looks inexpensive as its novel imatinib oral pro-drug IkT-001Pro will enter Phase 2B for PAH, with an added free Parkinson's call option for oral risvodetinib, where expectations are super low, the analyst tells investors in a research note.
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$15 → $5
2024-10-14
Reason
HC Wainwright & Co.
Edward White
Price Target
$15 → $5
2024-10-14
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$23 → $15
2024-08-16
Reason
HC Wainwright & Co.
Edward White
Price Target
$23 → $15
2024-08-16
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Inhibikase Therapeutics Inc (IKT.O) is -4.66, compared to its 5-year average forward P/E of -3.38. For a more detailed relative valuation and DCF analysis to assess Inhibikase Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.38
Current PE
-4.66
Overvalued PE
-0.21
Undervalued PE
-6.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
29.05
Current PS
0.00
Overvalued PS
65.56
Undervalued PS
-7.46
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+229.60%
-15.76M
Operating Profit
FY2025Q1
YoY :
+194.19%
-13.68M
Net Income after Tax
FY2025Q1
YoY :
-79.45%
-0.15
EPS - Diluted
FY2025Q1
YoY :
+17.81%
-4.56M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
2.7M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
580.6K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
5
30.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
2.7M
USD
Months
IKT News & Events
Events Timeline
2025-04-14 (ET)
2025-04-14
08:14:43
Inhibikase Therapeutics announces appointment of McIntyre as CFO

2025-02-24 (ET)
2025-02-24
08:14:17
Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO

2025-02-18 (ET)
2025-02-18
08:21:24
Inhibikase Therapeutics appoints Mark Iwicki as CEO

Sign Up For More Events
Sign Up For More Events
News
9.5
05-14NewsfilterInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
7.0
05-05PRnewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
5.0
04-14NewsfilterInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Sign Up For More News
People Also Watch

STFS
Star Fashion Culture Holdings Ltd
1.830
USD
-1.08%

RCKY
Rocky Brands Inc
23.540
USD
-1.26%

ACRV
Acrivon Therapeutics Inc
1.460
USD
+2.10%

CMCL
Caledonia Mining Corporation PLC
20.810
USD
-3.70%

CYBN
Cybin Inc
7.810
USD
-2.25%

CCRD
CoreCard Corp
27.980
USD
+2.38%

ISSC
Innovative Solutions and Support Inc
15.670
USD
+1.29%

TCX
Tucows Inc
20.610
USD
0.00%
FAQ

What is Inhibikase Therapeutics Inc (IKT) stock price today?
The current price of IKT is 1.79 USD — it has increased 1.13 % in the last trading day.

What is Inhibikase Therapeutics Inc (IKT)'s business?

What is the price predicton of IKT Stock?

What is Inhibikase Therapeutics Inc (IKT)'s revenue for the last quarter?

What is Inhibikase Therapeutics Inc (IKT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Inhibikase Therapeutics Inc (IKT)'s fundamentals?

How many employees does Inhibikase Therapeutics Inc (IKT). have?
